research use only

Amphotericin B Antibiotics for Mammalian Cell Culture inhibitor

Name: Amphotericin B
SKU: S1636
Availability: InStock
Rating: 5 (15 reviews)

Cat.No.S1636

Amphotericin B (AMB, NSC 527017) is an amphipathic polyene antibiotic which permeabilizes ergosterol-containing membranes.

Chemical Structure

Molecular Weight: 924.08

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.61%

99.61

Related Targets	Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease SARS-CoV HIV Protease Influenza Virus β-lactamase Integrase HBV CMV Neuraminidase HCV Thioredoxin Reductase HSV RSV Enterovirus 3C-Like Protease Ribosomal Peptidyl Transferase HPV
Related Products	Tylosin tartrate

Chemical Information, Storage & Stability

Molecular Weight	924.08	Formula	C₄₇H₇₃NO₁₇	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1397-89-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	NSC 527017			Smiles	CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O

Solubility

In vitro
Batch:

DMSO : 4.5 mg/mL (4.86 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 4.5 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.220mg/ml (0.24mM)	Taking the 1 mL working solution as an example, add 50 μL of 4.4 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.220mg/ml (0.24mM)	Taking the 1 mL working solution as an example, add 50 μL of 4.4 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	ergosterol ^[1]
In vitro	Amphotericin B administration is limited by infusion-related toxicity, including fever and chills, an effect postulated to result from proinflammatory cytokine production by innate immune cells. This compound induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14. ^[1] It interacts with cholesterol, the major sterol of mammal membranes, thus limiting the usefulness of this chemical due to its relatively high toxicity. This drug is dispersed as a pre-micellar or as a highly aggregated state in the subphase. ^[2] It only kills unicellular Leishmania promastigotes (LPs) when aqueous pores permeable to small cations and anions are formed. This compound (0.1 mM) induces a polarization potential, indicating K+ leakage in KCl-loaded liposomes suspended in an iso-osmotic sucrose solution. It (0.05 mM) exhibits a nearly total collapse of the negative membrane potential, indicating Na+ entry into the cells. ^[3]
In vivo	Amphotericin B results in prolonging the incubation time and decreasing PrPSc accumulation in the hamster scrapie model. This compound markedly reduces PrPSc levels in mice with transmissible subacute spongiform encephalopathies (TSSE). ^[4] It exerts a direct effect on Plasmodium falciparum and influences eryptosis of infected erythrocytes, parasitemia and hostsurvival in murine malaria. This chemical tends to delay the increase of parasitemia and significantly delays host death plasmodium berghei-infected mice. ^[5]
References	[1] https://pubmed.ncbi.nlm.nih.gov/12860979/ [2] https://pubmed.ncbi.nlm.nih.gov/9138890/ [3] https://pubmed.ncbi.nlm.nih.gov/8660406/ [4] https://pubmed.ncbi.nlm.nih.gov/7915757/ [5] https://pubmed.ncbi.nlm.nih.gov/12741794/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05593666	Recruiting	Primary Visceral Leishmaniasis	Drugs for Neglected Diseases\|Novartis Pharmaceuticals	December 27 2022	Phase 2
NCT05108545	Unknown status	Neutropenia and Fever	CSPC ZhongQi Pharmaceutical Technology Co. Ltd.	December 15 2021	Phase 3
NCT04993222	Completed	Bioequivalence	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.	June 4 2020	Phase 1
NCT03905447	Terminated	Aspergillosis\|Lung Transplant Infection	Pulmocide Ltd	September 17 2019	Phase 2
NCT03828773	Recruiting	Candidiasis\|Fungal Infection\|Acute Myeloid Leukemia\|Genetic Predisposition\|Aspergillosis	Bochud Pierre-Yves\|Swiss National Science Foundation\|Centre Hospitalier Universitaire Vaudois	February 11 2019	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):